HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction.

MLA

Papp, Eszter, et al. “HIV Protease Inhibitor Use during Pregnancy Is Associated with Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.” Journal of Infectious Diseases, vol. 211, no. 1, Jan. 2015, pp. 10–18. EBSCOhost, https://doi.org/10.1093/infdis/jiu393.

APA

Papp, E., Mohammadi, H., Loutfy, M. R., Yudin, M. H., Murphy, K. E., Walmsley, S. L., Shah, R., MacGillivray, J., Silverman, M., & Serghides, L. (2015). HIV protease inhibitor use during pregnancy is associated with decreased progesterone levels, suggesting a potential mechanism contributing to fetal growth restriction. Journal of Infectious Diseases, 211(1), 10–18. https://doi.org/10.1093/infdis/jiu393

Chicago

Papp, Eszter, Hakimeh Mohammadi, Mona R Loutfy, Mark H Yudin, Kellie E Murphy, Sharon L Walmsley, Rajiv Shah, Jay MacGillivray, Michael Silverman, and Lena Serghides. 2015. “HIV Protease Inhibitor Use during Pregnancy Is Associated with Decreased Progesterone Levels, Suggesting a Potential Mechanism Contributing to Fetal Growth Restriction.” Journal of Infectious Diseases 211 (1): 10–18. doi:10.1093/infdis/jiu393.